These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37952502)

  • 1. Dimethyl fumarate treatment in relapsing remitting MS changes the inflammatory CSF protein profile by a prominent decrease in T-helper 1 immunity.
    Hojjati S; Ernerudh J; Vrethem M; Mellergård J; Raffetseder J
    Mult Scler Relat Disord; 2023 Dec; 80():105126. PubMed ID: 37952502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
    Li R; Rezk A; Ghadiri M; Luessi F; Zipp F; Li H; Giacomini PS; Antel J; Bar-Or A
    J Immunol; 2017 Jan; 198(2):691-698. PubMed ID: 27974457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
    Edwards KR; Kamath A; Button J; Kamath V; Mendoza JP; Zhu B; Plavina T; Woodward C; Penner N
    Mult Scler Relat Disord; 2021 Jun; 51():102861. PubMed ID: 33773271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
    Sejbaek T; Nielsen HH; Penner N; Plavina T; Mendoza JP; Martin NA; Elkjaer ML; Ravnborg MH; Illes Z
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1324-1330. PubMed ID: 31611264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment.
    Mansilla MJ; Navarro-Barriuso J; Presas-Rodríguez S; Teniente-Serra A; Quirant-Sánchez B; Ramo-Tello C; Martínez-Cáceres EM
    CNS Neurosci Ther; 2019 Sep; 25(9):995-1005. PubMed ID: 31066225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.
    Yadav SK; Soin D; Ito K; Dhib-Jalbut S
    J Mol Med (Berl); 2019 Apr; 97(4):463-472. PubMed ID: 30820593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment with dimethyl fumarate in a child with relapsing-remitting multiple sclerosis.
    Saijo N; Abe Y; Oikawa Y; Okubo Y; Endo W; Numata-Uematsu Y; Takahashi T; Uematsu M
    Brain Dev; 2022 May; 44(5):353-356. PubMed ID: 35058083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
    Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
    Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects Mediated by Dimethyl Fumarate on In Vitro Oligodendrocytes: Implications in Multiple Sclerosis.
    Guerriero C; Puliatti G; Di Marino T; Tata AM
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.
    Holm Hansen R; Højsgaard Chow H; Sellebjerg F; Rode von Essen M
    Mult Scler; 2019 Aug; 25(9):1289-1297. PubMed ID: 30043661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis].
    Alifirova VM; Boiko AN; Vlasov YV; Davydovskaya MV; Zakharova MN; Malkova NA; Popova EV; Sivertseva SA; Spirin NN; Khachanova NV; Shmidt ТЕ
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(1):97-102. PubMed ID: 28252608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions.
    Zinger N; Ponath G; Sweeney E; Nguyen TD; Lo CH; Diaz I; Dimov A; Teng L; Zexter L; Comunale J; Wang Y; Pitt D; Gauthier SA
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis.
    Diebold M; Galli E; Kopf A; Sanderson NSR; Callegari I; Benkert P; Gonzalo Núñez N; Ingelfinger F; Herms S; Cichon S; Kappos L; Kuhle J; Becher B; Claassen M; Derfuss T
    Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2205042119. PubMed ID: 35881799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis.
    Tsantes E; Curti E; Ferraro D; Lugaresi A; Baldi E; Montepietra S; Immovilli P; Simone AM; Mancinelli L; Strumia S; Vitetta F; Foschi M; Ferri C; Ferrarini C; Sola P; Granella F
    Eur J Neurol; 2021 Jan; 28(1):269-277. PubMed ID: 32931130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate.
    Jožef M; Locatelli I; Brecl Jakob G; Rot U; Kos M
    Mult Scler Relat Disord; 2023 Apr; 72():104615. PubMed ID: 36933300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma.
    Ntranos A; Park HJ; Wentling M; Tolstikov V; Amatruda M; Inbar B; Kim-Schulze S; Frazier C; Button J; Kiebish MA; Lublin F; Edwards K; Casaccia P
    Brain; 2022 Apr; 145(2):569-583. PubMed ID: 34894211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for novel cell defense mechanisms sustained by dimethyl fumarate in multiple sclerosis patients: the HuR/SOD2 cascade.
    Mallucci G; Marchesi N; Campagnoli LIM; Boschi F; Fahmideh F; Fusco S; Tavazzi E; Govoni S; Bergamaschi R; Pascale A
    Mult Scler Relat Disord; 2022 Dec; 68():104197. PubMed ID: 36270254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.